ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Infection"

  • Abstract Number: 466 • 2014 ACR/ARHP Annual Meeting

    Should Anti-Tnfa  treatment of RA be Stopped before Orthopedic Surgery?

    Charlotte Mabille1, Adeline Ruyssen Witrand2, Thomas Barnetche3,4, Arnaud Constantin5 and Alain G. Cantagrel5, 1Rheumatology Unit, hopital Purpan, Toulouse, France, 2Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, 3rheumatology, Rheumatology department, Bordeaux University Hospital, bordeaux, France, 4Rheumatology department, Bordeaux University Hospital, bordeaux, France, 5Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France

    Background/Purpose Anti-TNFs have greatly contributed to improve RA prognosis. Hence, the needs for orthopedic surgery have considerably decreased in the past years. However, surgery, whether…
  • Abstract Number: 458 • 2014 ACR/ARHP Annual Meeting

    Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials

    V. Strand1, S. Ahadieh2, J. French3, J. Geier4, S. Krishnaswami5, S. Menon5, T. Checchio2, R. Riese6 and J. Gomez-Reino7, 1Biopharmaceutical Consultant, Portola Valley, CA, 2Pharmacometrics, Pfizer Inc, Groton, CT, 3Metrum Research Group, Tariffville, CT, 4Pfizer Inc, New York, NY, 5Clinical Pharmacology, Pfizer Inc, Groton, CT, 6Pfizer Inc, Groton, CT, 7Hospital Clinico, Universitario de Santiago, Santiago, Spain

    Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Serious infection events (SIEs) have been reported in the tofacitinib…
  • Abstract Number: 2775 • 2014 ACR/ARHP Annual Meeting

    Cutaneous Vasculitis Associated with Severe Bacterial Infections. Study of 27 Patients from a Series of 766 Cutaneous Vasculitis

    Leyre Riancho-Zarrabeitia1, Javier Loricera1, Ricardo Blanco1, Jose L. Hernández2, Vanesa Calvo-Río1, Francisco Ortiz Sanjuan1, Cristina Mata-Arnaiz1, Javier Rueda-Gotor1, Lino Álvarez3, Carmen Gonzalez-Vela4, Marcos A. González-López5, Susana Armesto5, Trinitario Pina Murcia6, Montserrat Santos-Gómez1 and Miguel A. González-Gay1, 1Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 3Pediatrics, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 4Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 5Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 6Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain

    Background/Purpose: To assess the clinical spectrum of severe bacterial infections presenting as cutaneous vasculitis (CV) in a defined population. Methods: Unselected series of 766 patients…
  • Abstract Number: 57 • 2014 ACR/ARHP Annual Meeting

    Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort

    Kevin L. Winthrop1, Lang Chen2, John Baddley2, Allison Taylor3, Benjamin Chan4, Huifeng Yun5, Sarah Siegel6 and Jeffrey R. Curtis7, 1Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, 2Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 4Oregon Health and Science University, Portland, OR, 5Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, 6Oregon Health & Science University, Portland, OR, 7The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Psoriasis (PsO)/Psoriatic arthritis (PsA) often requires treatment with systemic immunosuppressive agents, some of which may increase hospitalized infection risk. Few population-based studies to date…
  • Abstract Number: 2152 • 2014 ACR/ARHP Annual Meeting

    Frequency of Postoperative Deep Infection in Patients with Rheumatoid Arthritis

    Masayuki Azukizawa and Hiromu Ito, Orthopaedic surgery, Kyoto University, Kyoto, Japan

    Background/Purpose: Rheumatoid arthritis (RA) is known to be associated with an increased risk of serious infection. It has been discussed about the risk of the…
  • Abstract Number: 1370 • 2013 ACR/ARHP Annual Meeting

    Prednisone Is a Risk Factor For Pneumocystis Jirovecii Pneumonia In Patients With Rheumatic Diseases: A Case-Control Study With 36 Cases

    Wieneke van den Hombergh1, Annelies van Ede2, J. Fransen3, Femke BG lamers-Karnebeek3, Saskia Kuipers4 and Matthijs Janssen5, 1Rheumatology, UMC st. Radboud, Nijmegen, Netherlands, 2Rheumatology, UMC st Radboud, Nijmegen, Netherlands, 3Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4Microbiology, UMC st Radboud, Nijmegen, Netherlands, 5Department of Rheumatology, Rijnstate Hospital, Arnhem, Netherlands

     Background/Purpose: Pneumocystis jirovecii is a fungal pathogen that causes pneumonia in immunocompromized hosts. Prednisone is frequently suggested as a risk factor for developing pneumocystis pneumonia (PCP) in patients with rheumatic diseases. If prednisone…
  • Abstract Number: 1276 • 2013 ACR/ARHP Annual Meeting

    Immunologic Monitoring and Infectious Complications In Pediatric Rheumatology Patients Treated With Rituximab

    Alysha Taxter1, Kathleen E. Sullivan2 and Jon Burnham3, 1Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, 2Immunology ARC 1216, The Children's Hospital of Philadelphia, Philadelphia, PA, 3Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Rituximab is an anti-CD20 monoclonal antibody increasingly used in immunologic and malignant conditions to deplete B cells. Suppression of humoral immunity after rituximab exposure may…
  • Abstract Number: 1046 • 2013 ACR/ARHP Annual Meeting

    Comparison Of The Incidence Of Influenza Like Illness In Pregnant Women With Rheumatoid Arthritis and Women Without Rheumatoid Arthritis Who Receive An Influenza Vaccination

    Yunjun Luo1, Diana L. Johnson2, Ronghui Xu3 and Christina D. Chambers1, 1Pediatrics, University of California, San Diego, La Jolla, CA, 2University of California San Diego Department of Pediatrics, La Jolla, CA, 3Family and Preventive Medicine, University of California, San Diego, La Jolla, CA

    Background/Purpose: Influenza infection poses significant risk to pregnant women, therefore it is recommended that all pregnant women be vaccinated. However, it is unknown whether the…
  • Abstract Number: 803 • 2013 ACR/ARHP Annual Meeting

    The Risk Of Serious Infections In Patients Receiving Rituximab For Rheumatoid Arthritis: Results From The British Society For Rheumatology Biologics Register-Rheumatoid Arthritis

    Lucía Silva-Fernández1,2, Mark Lunt3, Audrey S. Low2, Kath D. Watson3, BSRBR Control Centre Consortium2, Deborah P. Symmons2, Kimme L. Hyrich4 and On behalf of the BSRBR5, 1Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, 2Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, 3Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 4Arthritis Research UK Epidemiology Unit, Manchester Academic Health Sciences Centre, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 5British Society for Rheumatology, London, United Kingdom

    Background/Purpose: In the United Kingdom (UK), rituximab (RTX), an anti-CD20 monoclonal antibody, is currently used to treat patients with rheumatoid arthritis (RA) who have failed…
  • Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting

    Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study

    Zaki AbouZahr1, Andrew Spiegelman2, Maria Cantu3 and Bernard Ng4, 1Baylor College of Medicine, Houston, TX, 2Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, 3Baylor College Of Medicine, Houston, TX, 4Michael E. DeBakey VA Medical Center, Houston, TX

    Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
  • Abstract Number: 780 • 2013 ACR/ARHP Annual Meeting

    Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants

    Candace H. Feldman1, Linda T. Hiraki2, Francisco M. Marty3, Wolfgang C. Winkelmayer4, Jessica M. Franklin5, Daniel H. Solomon6,7, Seoyoung C. Kim8 and Karen H. Costenbader9, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, 3Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, 4Division of Nephrology, Stanford University School of Medicine, Stanford, CA, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 6Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 7Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, 8Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 9Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

    Background/Purpose: Infections are among the leading causes of hospitalization and mortality in patients with systemic lupus erythematosus (SLE); approximately 50% have a serious infection during…
  • Abstract Number: 730 • 2013 ACR/ARHP Annual Meeting

    Cell-Mediated Immune Responses To Influenza and Herpesvirus Antigen Stimulation Are Conserved But Adversely Impacted By Immunosuppressive Therapy and Active Infection In Patients With Granulomatosis With Polyangiitis

    John McKinnon1, Robbie Mailliard2, Dawn McClemens-McBride3, Donald Jones3, Charles Rinaldo Jr.4 and Kathleen Maksimowicz-McKinnon5, 1Infectious Disease, Henry Ford Hospital, Detroit, MI, 2Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, 3Rheumatology, University of Pittsburgh, Pittsburgh, PA, 4Infectious Diseases and Microbiology, Pathology, University of Pittsburgh, Pittsburgh, PA, 5Rheumatology, Henry Ford Hospital, Detroit, MI

    Background/Purpose: Reactivation of chronic herpesvirus infections is not uncommon in immunosuppressed patients, including those with granulomatosis with polyangiitis (GPA).  The effects of GPA disease and…
  • Abstract Number: 744 • 2013 ACR/ARHP Annual Meeting

    Relationship Between Infectious Side Effects and Immunoglobulin Levels In The Maintenance Rituximab Vs Azathioprine For ANCA-Associated Vasculitides Trial

    Loic Guillevin1, Christian Pagnoux2, Alexandre Karras3, Chahera Khouatra4, Olivier Aumaître5, Pascal Cohen6, Olivier Decaux7, Hélène Desmurs-Clavel8, Pierre Gobert9, Thomas Quemeneur10, Claire Blanchard-Delaunay11, Pascal Godmer12, Xavier Puechal13, Pierre-Louis Carron14, Pierre-Yves Hatron15, Nicolas Limal16, Mohamed Hamidou17, Francois Maurier18, Thomas Papo19, Matthias Büchler20, Bernard Bonnotte21, Philippe Ravaud22 and Luc Mouthon23, 1Internal Medicine, Division of Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France, 2Internal Medicine, Hôpital Cochin, PARIS, France, 3Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, 4CHU Lyon, Lyon, France, 5Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, 6National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, 7Department of Internal Medicine, Rennes University Hospital, Rennes, France, 8University of Lyon, LYON, France, 9Nephrology, Centre Hospitalier d'Avignon, Avignon, France, 10Internal medicine, CHR de Valenciennes, Valenciennes, France, 11Internal Medicine, Hôpital de Niort, Niort, France, 12Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, 13Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, 14Internal Medicine, Centre Hospitalier de Grenoble, Grenoble, France, 15Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, 16Department of Internal Medicine, Hôpital Henri Mondor, APHP, Creteil, France, 17Internal Medicine Department, Nantes University Hospital, Nantes, France, 18HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, 19Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 20Nephrology, University Hospital of Tours, TOURS, France, 21Department of Internal Medicine, Centre Hospitalier de Dijon, Dijon, France, 22Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, 23Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France

    Background/Purpose: MAINRITSAN trial (NCT 00748644) results demonstrated that 500 mg of rituximab (RTX) every 6 months was superior to azathioprine (AZA) to maintain ANCA-associated–vasculitis (AAV)…
  • Abstract Number: 745 • 2013 ACR/ARHP Annual Meeting

    Rate Of Infection and Development Of Malignancy In Patients With ANCA-Associated Vasculitis Treated With Rituximab: A Meta-Analysis From Randomized Trials

    Carolina Mejia-Otero1, Carlos J. Lozada2 and Luis Arias-Urdaneta3, 1Internal Medicine, Mount Sinai Medical Center, Miami, FL, 2Dept of Medicine/Rheumatology, University of Miami Miller School of Medicine, Miami, FL, 3Rheumatology, Mount Sinai Medical Center, Miami Beach, FL

    Background/Purpose: Over the past 40 years failures to achieve remission in a proportion of patients and the potential development of significant adverse effects have been…
  • Abstract Number: 2679 • 2013 ACR/ARHP Annual Meeting

    Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication Use

    Linda T. Hiraki1, Candace H. Feldman2, Mary Beth Son3, Jessica M. Franklin4, Michael A. Fischer4, Daniel H. Solomon5, Seoyoung C. Kim6, Wolfgang C. Winkelmayer7 and Karen H. Costenbader2, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Immunology, Boston Children's Hospital, Boston, MA, 4Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 5Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, 6Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 7Division of Nephrology, Stanford University School of Medicine, Stanford, CA

    Incidence Rates Of Serious Infections and Infection Subtypes Among Pediatric Systemic Lupus Erythematosus Patients Enrolled In Medicaid, According To Medication UseBackground/Purpose: We investigated incidence rates…
  • « Previous Page
  • 1
  • …
  • 28
  • 29
  • 30
  • 31
  • 32
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology